Aesthetics · LCY Science Check
Exosome Skincare: What Regulators Say, What Studies Show
Exosome serums and treatments promise regeneration. Early human studies are encouraging but small, and the US FDA says no exosome product is approved.
Key takeaway: Early human studies of exosome products report short-term improvements, but they are small, mostly non-randomised and hard to compare, and the products themselves are not standardised. In the US, the FDA states that no exosome product is approved, and it has warned about serious harms linked to unapproved ones.
What are exosomes?
Exosomes are tiny membrane-bound vesicles that cells release to communicate with each other. They carry proteins, fats and genetic material. In aesthetics the word covers a wide range of products: vesicles collected from human cells, plants or bacteria, sold as serums, applied after microneedling or injected. What is in a given bottle is rarely standardised or independently verified, and a scoping review of the market found that commercial products give minimal information on how their exosomes were isolated.
Why it could work
In cell and animal studies, exosomes have been shown to influence collagen production and inflammation through cell signalling, which is why they attract interest for skin rejuvenation and hair. Turning that into a predictable clinical effect from a commercial product is the hard part. Dose, purity, delivery and consistency between batches are all open questions.
What human studies show
Several reviews have gathered the human data. A 2026 systematic review of human studies in Cureus included 19 studies, most of them not randomised, and linked exosome interventions with short-term improvements in hydration, elasticity, wrinkles, pores and pigmentation. A meta-analysis in Aesthetic Surgery Journal estimated an average facial wrinkle reduction of about 20%, but its authors caution that differences between studies limit firm conclusions. A separate scoping review of topical exosomes screened 2,394 articles and found only 18 clinical studies, describing human evidence as scarce and much of the case as extrapolated from preclinical models.
What regulators say
On 6 December 2019 the US Food and Drug Administration issued a public safety notification after reports of serious adverse events in patients in Nebraska who had been treated with unapproved products marketed as containing exosomes. The FDA states that there are no FDA-approved exosome products, and that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, which need premarket review and approval. A 2026 review in Dermatological Reviews notes that by October 2023 the agency had issued six public safety notifications and warning letters following reports of adverse events.
As a general rule under US law, a product intended only to cleanse or beautify is a cosmetic, while a product claimed to change how skin functions can be treated as a drug. Rules differ in other countries, so check your local regulator.
Safety
Reviews describe topical use as generally well tolerated in the studies they include, with individual reports of harm linked to off-label injection. The bigger safety issue is product quality. Without standardisation or approval, sterility, source and contents cannot be assumed. If you are offered an exosome injection, ask what exactly the product is, who made it, how it is classified where you live and what happens if something goes wrong.
The LCY verdict
Trend: rising. Exosomes are discussed widely in regenerative aesthetics and in regulatory and legal commentary. That is a qualitative editorial call. We have not quantified search or social volume.
Evidence: D (Weak) for skin and hair claims. Human studies exist and are encouraging, but they are small, mostly non-randomised and too varied to support firm conclusions.
The evidence box
| THE LCY EVIDENCE BOX | Our assessment |
|---|---|
| THE CLAIM | Exosome serums and treatments regenerate skin and hair. |
| WHY IT COULD WORK | Cell and animal studies show effects on collagen production and inflammation through cell signalling. This is mechanism only. |
| WHAT HUMAN STUDIES SHOW | A 2026 systematic review of 19 human studies (mostly non-randomised) reports short-term improvements. A meta-analysis estimates an average wrinkle reduction of about 20%. A scoping review found only 18 topical clinical studies. |
| QUALITY OF EVIDENCE | Small, varied, mostly non-randomised, limited follow-up, and non-standardised products. |
| CLINICAL SIGNIFICANCE | Unclear. Reported percentage changes come from mixed methods and cannot be assumed to apply to a specific product. |
| SAFETY | Topical use is generally reported as well tolerated in studies. There are individual reports of harm with off-label injection, and in 2019 the FDA warned of serious adverse events linked to unapproved products. |
| REGULATORY STATUS | US: no FDA-approved exosome products; regulated as drugs and biological products when used to treat conditions. Other countries differ. |
| WHO FUNDED THE STUDY / CONFLICTS | Sourcing and funding vary widely. Commercial products often disclose little about how exosomes are isolated or what they contain. |
| LCY EVIDENCE METER | D (Weak) for skin and hair claims. |
| WHAT WE STILL DON'T KNOW | Which sources and doses work; whether topical exosomes reach target layers; long-term safety; how results compare with established treatments. |
What we know
Human studies report short-term improvements, but most are small and non-randomised.
Commercial products vary in source and disclose little about how they are made.
The FDA states that no exosome product is approved and has warned of serious harms linked to unapproved ones.
What we don't know
Which sources, doses and delivery methods work.
Whether topical products reach the layers where they are meant to act.
Long-term safety, and how results compare with established treatments.
Sources
Public Safety Notification on Exosome Products (opens in a new tab) (US FDA, 6 December 2019)
Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies (opens in a new tab) (Cureus, 2026)
Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials (opens in a new tab) (Aesthetic Surgery Journal, 2025)
Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review (opens in a new tab) (Aesthetic Surgery Journal)
Regulatory, Ethical, and Safety Considerations of Exosome-Based Therapies in Dermatology (opens in a new tab) (Dermatological Reviews, 2026)
Editorial evidence review. This article was prepared from the sources listed above and has not yet been reviewed by a named medical or cosmetic-science expert. It is general information, not medical advice. Images are illustrative and generated with AI.
